Ahmed M Abbas*, Fatma M Helbawi and Mostafa H Abdelsalam
Volume1-Issue5
Dates: Received: 2020-08-21 | Accepted: 2020-09-16 | Published: 2020-09-18
Pages: 160-162
Abstract
A new type of pneumonia had developed from Wuhan Province in China in December 2019, caused by a novel member of the Coronaviridae family named Severe Acute Respiratory Coronavirus 2 Syndrome (SARS-CoV-2) [1]. The disease is characterized by fatigue, dry cough, fever, and dyspnea [2]. In a more severe case, the picture may become more complicated by the onset of interstitial pneumonia with alveolar damage, which clinically can lead to severe Acute Respiratory Distress Syndrome (ARDS) and even death [3]. Since the initial outbreak, the epidemic has had a rapid global spread worldwide, which led the World Health Organization (WHO) to declare the disease now called COVID-19, a pandemic on 11th March 2020 [4].
FullText HTML
FullText PDF
DOI: 10.37871/jbres1137
Certificate of Publication
Copyright
© 2020 Abbas AM, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Abbas AM, Helbawi FM, Abdelsalam MH. Treatment of People with Evans Syndrome in the Setting of COVID-19 Pandemic. J Biomed Res Environ Sci. 2020 Sep 18; 1(5): 160-162. doi: 10.37871/jbres1137, Article ID: jbres1137
Subject area(s)
University/Institute
References
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-273. DOI: 10.1038/s41586-020-2012-7
- Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020. DOI: 10.1001/jama.2020.2648
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475-481. DOI: 10.1016/S2213-2600(20)30079-5
- https://experience.arcgis.com/experience/685d0ace521648f8a5beee1b9125cd (Accessed 20th August 2020).
- Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev. 2020; 19: 102523. DOI: 10.1016/j.autrev.2020.102523
- Barcellini W, Giannotta J, Fattizzo B. Autoimmune hemolytic anemia in adults: Primary risk factors and diagnostic procedures. Exp Rev Hematol. 2020; 13: 585-597. DOI: 10.1080/17474086.2020.1754791
- Mendonca S, Srivastava S, Kapoor R, Gupta D, Gupta P, Sharma ML. Evans syndrome and its link with systemic lupus erythematosus. Saudi J Kidney Dis Transpl. 2016; 27: 147-149. DOI: 10.4103/1319-2442.174177
- Rodeghiero F, Marranconi E. Management of immune thrombocytopenia in women: Current standards and special considerations. Exp Rev Hematol. 2020; 13: 175-185. DOI: 10.1080/17474086.2020.1711729
- Tang NL, Chan PK, Wong CK, To KF, Wu AK, Sung YM, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem. 2005; 51: 2333-2340. DOI: 10.1373/clinchem.2005.054460
- Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018; 197: 757-767. DOI: 10.1164/rccm.201706-1172OC
- Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS medicine. 2006; 3: e343. DOI: https://dx.doi.org/10.1371/journal.pmed.0030343
- Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015; 386: 995-1007. DOI: 10.1016/S0140-6736(15)60454-8
- Rosa SG, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública. 2020; 44: e40. DOI: 10.26633/RPSP.2020.40
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395: 473-475. DOI: 10.1016/S0140-6736(20)30317-2
- Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72-73. DOI: 10.5582/bst.2020.01047
- Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ. 2020; 49: 215-219. DOI: 10.3785/j.issn.1008-9292.2020.03.03
- Parperis K. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV- 2(COVID-19) pandemic. Ann Rheum Dis. 2020; annrheumdis-2020-217557. DOI: 10.1136/annrheumdis-2020-217557
- Papachristodoulou E, Kakoullis L, Parperis K, Panos G. Long-term and herd immunity against SARS-CoV-2: Implications from current and past knowledge. Pathog Dis. 2020; 78. DOI: 10.1093/femspd/ftaa025
